The limited efficacy and intolerable toxicities reported in these studies emphasize the urgent need for stratifying biomarkers for the upfront selection of CRC patients who could potentially benefit from Hsp90 inhibitor therapy. This evidence concerns the gene HSP90AA1 and colorectal carcinoma.